ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and Nexalin Technology (NASDAQ:NXL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.
Valuation and Earnings
This table compares ENDRA Life Sciences and Nexalin Technology”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ENDRA Life Sciences | N/A | N/A | -$10.06 million | ($901.15) | -0.01 |
| Nexalin Technology | $110,000.00 | 488.68 | -$4.65 million | ($0.64) | -6.53 |
Nexalin Technology has higher revenue and earnings than ENDRA Life Sciences. Nexalin Technology is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Analyst Ratings
This is a breakdown of current recommendations for ENDRA Life Sciences and Nexalin Technology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ENDRA Life Sciences | 0 | 0 | 1 | 0 | 3.00 |
| Nexalin Technology | 0 | 0 | 1 | 0 | 3.00 |
ENDRA Life Sciences presently has a consensus target price of $700,000.00, suggesting a potential upside of 12,259,094.40%. Nexalin Technology has a consensus target price of $3.00, suggesting a potential downside of 28.23%. Given ENDRA Life Sciences’ higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Nexalin Technology.
Profitability
This table compares ENDRA Life Sciences and Nexalin Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ENDRA Life Sciences | N/A | -127.39% | -103.77% |
| Nexalin Technology | -3,407.98% | -187.59% | -167.21% |
Institutional and Insider Ownership
1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 0.0% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 24.0% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
ENDRA Life Sciences beats Nexalin Technology on 6 of the 11 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
